ethyl 6-{[4-(4-methylaminophenyl)-6-phenyl-2-pyridyl]oxy}hexanoate | 141748-16-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: ethyl 6-{[4-(4-methylaminophenyl)-6-phenyl-2-pyridyl]oxy}hexanoate
• 英文别名: ethyl 6-[4-[4-(methylamino)phenyl]-6-phenylpyridin-2-yl]oxyhexanoate
• CAS: 141748-16-5
• 化学式: C₂₆H₃₀N₂O₃
• 分子量: 418.536
• InChiKey: VJWUFXXRSAARGM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  31
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  60.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 6-{[4-(4-methylaminophenyl)-6-phenyl-2-pyridyl]oxy}hexanoate 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 反应 4.0h， 生成 6-<<4-<4-(methylamino)phenyl>-6-phenyl-2-pyridyl>oxy>hexanoic acid
  参考文献：
  名称：

  .omega.-[(4,6-Diphenyl-2-pyridyl)oxy]alkanoic acid derivatives: a new family of potent and orally active LTB4 antagonists

  摘要：

  A series of omega-[(4,6-diphenyl-2-pyridyl)oxy]alkanoic acid derivatives was prepared which inhibited the binding of leukotriene B4 to its receptors on guinea pig spleen membranes and on human polymorphonuclear leukocytes (PMNs) and selectively antagonized the LTB4-induced elastase release in human PMNs. On the basis of these three screens, a structure-activity relationship was investigated. Alpha-Substitution on the carboxylic acid side chain led to only small changes in the binding affinities but greatly enhanced the LTB4 antagonist activity. Substitution on the phenyl rings was also evaluated. The terminal carboxylic acid function can be replaced by a tetrazole ring without loss in activity. The beat in vitro LTB4 antagonists of this series were investigated in vivo in the inhibition of LTB4-induced leukopenia in rabbits. Compound 9b (RP69698) displayed potent LTB4 antagonist activity, after oral administration, with an ED50 value of 6.7 mg/kg.

  DOI：

  10.1021/jm00101a008
• 作为产物：
  描述：

  6-溴己酸乙酯 在 sodium tetrahydroborate 、 silver carbonate 、 三氟乙酸 、 tin(ll) chloride 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 54.0h， 生成 ethyl 6-{[4-(4-methylaminophenyl)-6-phenyl-2-pyridyl]oxy}hexanoate
  参考文献：
  名称：

  .omega.-[(4,6-Diphenyl-2-pyridyl)oxy]alkanoic acid derivatives: a new family of potent and orally active LTB4 antagonists

  摘要：

  A series of omega-[(4,6-diphenyl-2-pyridyl)oxy]alkanoic acid derivatives was prepared which inhibited the binding of leukotriene B4 to its receptors on guinea pig spleen membranes and on human polymorphonuclear leukocytes (PMNs) and selectively antagonized the LTB4-induced elastase release in human PMNs. On the basis of these three screens, a structure-activity relationship was investigated. Alpha-Substitution on the carboxylic acid side chain led to only small changes in the binding affinities but greatly enhanced the LTB4 antagonist activity. Substitution on the phenyl rings was also evaluated. The terminal carboxylic acid function can be replaced by a tetrazole ring without loss in activity. The beat in vitro LTB4 antagonists of this series were investigated in vivo in the inhibition of LTB4-induced leukopenia in rabbits. Compound 9b (RP69698) displayed potent LTB4 antagonist activity, after oral administration, with an ED50 value of 6.7 mg/kg.

  DOI：

  10.1021/jm00101a008

文献信息

• Substituted quinolyl compounds exhibiting selective leukotriene B.sub.4
  申请人：Rhone-Poulenc Rorer S.A.

  公开号：US05492915A1

  公开（公告）日：1996-02-20

  This invention relates to compounds having selective LTB.sub.4 antagonist properties. Therapeutic compositions comprising said compounds and methods for the treatment of disorders involving LTB.sub.4 agonist-mediated activity utilizing said compositions wherein the compounds are described by the formula ##STR1## wherein R.sub.4, X, R, Y, R', Q, m and n are herein defined, and pharmaceutically acceptable salts thereof.

  本发明涉及具有选择性LTB.sub.4拮抗剂特性的化合物。包括该化合物的治疗组合物和使用该组合物治疗涉及LTB.sub.4激动剂介导的活性的疾病的方法，其中该化合物由以下式子描述：##STR1## 其中R.sub.4、X、R、Y、R'、Q、m和n在此定义，并且其药学上可接受的盐。
• Substituted bicyclic bis-aryl compounds exhibiting selective leukotriene
  申请人：Rhone-Poulenc Rorer S.A.

  公开号：US05366982A1

  公开（公告）日：1994-11-22

  This invention relates to compounds having selective LTB.sub.4 antagonist properties, compositions comprising said compounds and methods for the treatment of disorders involving LTB.sub.4 agonist-mediated activity utilizing said compositions wherein the compounds are described by the general formula ##STR1## and pharmaceutically acceptable salts thereof.

  本发明涉及具有选择性LTB.sub.4拮抗剂特性的化合物，包括该化合物的组合物和使用该组合物治疗涉及LTB.sub.4激动剂介导活性的疾病的方法，其中所述化合物由通式##STR1## 描述，以及其药学上可接受的盐。
• SUBSTITUTED BICYCLIC BIS-ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS
  申请人：RHONE-POULENC RORER S.A.

  公开号：EP0540604A1

  公开（公告）日：1993-05-12
• US5366982A
  申请人：——

  公开号：US5366982A

  公开（公告）日：1994-11-22
• US5492915A
  申请人：——

  公开号：US5492915A

  公开（公告）日：1996-02-20